




RealRate

PHARMACEUTICAL 2022

Arcturus Therapeutics Holdings Inc.
Rank 311 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

Arcturus Therapeutics Holdings Inc.
Rank 311 of 475



The relative strengths and weaknesses of Arcturus Therapeutics Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcturus Therapeutics Holdings Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 58% points. The greatest weakness of Arcturus Therapeutics Holdings Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 125% points.

The company's Economic Capital Ratio, given in the ranking table, is -207%, being 70% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	378,961
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	99,537
Liabilities, Non-Current	45,135
Other Assets	8,210
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	19,931
Other Net Income	-822
Property and Equipment	5,643
Research and Development	173,760
Revenues	12,359
Selling, General and Administrative Expense	41,451

Output Variable	Value in 1000 USD
Assets	392,814
Liabilities	164,603
Expenses	215,211
Stockholders Equity	228,211
Net Income	-203,674
Comprehensive Net Income	-203,674
Economic Capital Ratio	-207%

